Spyre Therapeutics (SYRE) Research & Development (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Research & Development data on file, last reported at $60.4 million in Q1 2026.

• Quarterly Research & Development rose 45.14% year-over-year to $60.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.4 million (up 12.36% YoY) and the FY2025 annual result came in at $171.7 million, up 5.44% from the prior year.
• Research & Development advanced to $60.4 million in Q1 2026, from $44.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $60.4 million in Q1 2026 to a low of $12.0 million in Q3 2022.
• A 5-year average of $31.9 million and a median of $33.7 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development fell 19.36% — and 2024, when it surged 153.54%.
• Tracing SYRE's Research & Development over 5 years: stood at $14.3 million in 2022, then soared by 136.35% to $33.7 million in 2023, then soared by 49.88% to $50.5 million in 2024, then decreased by 11.58% to $44.6 million in 2025, then jumped by 35.34% to $60.4 million in 2026.
• The last three Research & Development figures came in at $60.4 million (Q1 2026), $44.6 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.